Analyse Cytokinetics, Incorporated (CYTK) — Kairos Score 55/100

À propos de Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Informations clés

🕴️ Activité des initiés (90 jours)

22 transactions — 0 achats et 12 ventes déclarés par les dirigeants de Cytokinetics, Incorporated.

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur CYTK dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur CYTK.

• Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
• Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.